The guidelines also recommend using the medication in patients with a compelling need to minimize weight gain, patients prone to hypoglycemia, and patients who need a substantial A1C reduction [38]
Three of those trials were double-blind, randomized, placebo-controlled trials (along with 16 weeks of dose escalation)
Pharmacodynamic (PD) Studies: These studies examine the biological effects of a compound in the body
Triple-Hormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial Patient-friendly explanation of emerging weight-loss peptides FDAs Concerns with Unapproved GLP-1 Drugs Used for Weight Loss Real people, REAL RESULTS
Research Protocols: Reconstitution, Storage, and Dosing Researchers working with either compound in a laboratory setting should follow standardized peptide handling protocols
Vendors making this claim are either misinformed or deliberately misleading